Home/Filings/4/0001213900-25-094430
4//SEC Filing

Drugs Made In America Acquisition II LLC 4

Accession 0001213900-25-094430

CIK 0002040475other

Filed

Sep 30, 8:00 PM ET

Accepted

Oct 1, 10:37 AM ET

Size

11.1 KB

Accession

0001213900-25-094430

Insider Transaction Report

Form 4
Period: 2025-09-26
Transactions
  • Other

    Ordinary shares

    2025-09-26400,00014,675,000 total
  • Sale

    Ordinary shares

    2025-09-267,966,6676,708,333 total
  • Purchase

    Ordinary shares

    2025-09-26+700,00015,075,000 total
  • Purchase

    Rights to receive ordinary shares

    2025-09-26+700,000700,000 total
    Ordinary shares (700,000 underlying)
Footnotes (4)
  • [F1]Reflects 700,000 private units acquired by the reporting person, the Issuer's sponsor. Each private unit consists of one ordinary share and one right to receive one-tenth (1/10) of an ordinary share upon the consummation of an initial business combination. The private units were purchased at $10 per unit for an aggregate purchase price of $7,000,000.
  • [F2]As of the Transaction Date, the reporting person transferred an aggregate of 400,000 ordinary shares to certain of the Issuer's officers and directors for no consideration.
  • [F3]As of the Transaction Date, pursuant to share transfer agreements, the reporting person transferred an aggregate of 7,966,667 ordinary shares to a number of accredited investors for consideration ranging from no consideration to $1.50 per share.
  • [F4]The rights convert automatically into ordinary shares at the completion of the Issuer's initial business combination.

Documents

1 file

Issuer

Drugs Made In America Acquisition II Corp.

CIK 0002040475

Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0002088432

Filing Metadata

Form type
4
Filed
Sep 30, 8:00 PM ET
Accepted
Oct 1, 10:37 AM ET
Size
11.1 KB